# 510(K) SUMMARY

NOV 2 0 2012

Device Name:

GORE® DrySeal Sheath with

hydrophilic coating

**Proprietary Name:** 

GORE® DrySeal Sheath with

hydrophilic coating

Common Name:

Introducer Sheath

Classification Name:

Catheter, Introducer (per 870.1340)

**Device Classification:** 

Class II

**Product Code:** 

DYB

**Date Summary Prepared:** 

April 17, 2012

October 5, 2012, revised

**Contact Person:** 

Alicia L. Hemphill, M.S., RAC

Regulatory Affairs

Medical Products Division W. L. Gore & Associates, Inc.

3450 West Kiltie Lane Flagstaff, AZ 86002-0500

Telephone: (928) 864-4328 Facsimile: (928) 864-4304 E-mail: ahemphil@wlgore.com

# **Device Description**

The GORE® DrySeal Sheath consists of a hydrophilic coated introducer sheath with GORE® DrySeal Valve attached, a dilator, and a syringe.

The introducer sheath is a polyethylene tube with a tapered leading tip and marker band incorporated within the sheath material to allow identification under fluoroscopy. The sheath has an insert molded hub on the trailing end, which is attached to the GORE® DrySeal Valve.

The GORE® DrySeal Valve is comprised of an outer silicone tube and an inner film tube. The region between the silicone tube and film tube is pressurized by injecting 2.5mL of saline into the space, using the provided syringe, during procedural preparation of the device.

The dilator has a tapered leading end and provides dilatation of the access vessel. A mark on the trailing end of the dilator ensures correct positioning of the dilator within the sheath.

#### **Device Modification**

A hydrophilic coating has been added to the GORE® DrySeal Sheath. No other changes were made to the proposed device from that cleared under K093791.

# **Predicate Devices**

GORE® DrySeal Sheath with hydrophilic coating:

GORE® DrySeal Sheath (K093791)

## **Indications**

The GORE® DrySeal Sheath with hydrophilic coating is intended to be inserted in the vasculature to provide a conduit for the insertion of endovascular devices while minimizing blood loss associated with such insertions.

# **Biocompatibility**

Results for all biocompatibility testing demonstrate that the materials used

meet the requirements of ANSI/AAMI/ISO 10993.

Test	Test Description	Result (Pass/Fail)	
Cytotoxity	MEM Assay (qualitative)	Pass	
ISO 10993-5			
<sup>1</sup> Sensitization	Murine Local Lymph Node	Pass	
ISO 10993-10	Assay		
Intracutaneous	Intracutaneous Irritation Test	Pass	
Reactivity			
ISO 10993-10			
Acute System Toxicity	Acute Systemic Study in Mice	Pass	
ISO 10993-11	1		
ISO 10993-12			
Hemocompatibility	Complement Activation	Pass	
ISO 10993-4	Hemolysis Assay		
ISO 10993-12	In vivo Thrombogensis	1	
	Prothrombin Time Assay	<u> </u>	
Pyrogenicity	Rabbit Pyrogen Test	Pass	
ISO 10993-11			
ISO 10993-12			

<sup>&</sup>lt;sup>1</sup>Additional Sensitization Testing Submitted September 18, 2012

# **Substantial Equivalence**

#### GORE® DrySeal Sheath, W. L. Gore & Associates, K093791.

Documentation provided includes a detailed comparison which demonstrates that the proposed GORE® DrySeal Sheath hydrophilic coated introducer sheath is substantially equivalent to the predicate GORE® DrySeal Sheath cleared under K093791. A hydrophilic coating has been added to the GORE® DrySeal Sheath. No other changes were made to the introducer sheath, DrySeal Valve or dilator from that cleared under K093791.

Additionally, the following tests/evaluations were performed to confirm equivalence to the predicate device:

- Biocompatibility
- Sterilization Validations
- Packaging Integrity
- Product Shelf-Life

510(k) Premarket Notification GORE® DrySeal Sheath Conclusion (Statement of Equivalence)

Design Verification

Any differences in the technological characteristics do not raise any new issues of safety and efficacy.

The results demonstrate that the lubricity of the GORE® DrySeal Sheath with hydrophilic coating performs as designed, is suitable for its intended use, and that it is substantially equivalent to the predicate device.

# Conclusion

Any differences in the technological characteristics do not raise any new issues of safety and efficacy. In terms of intended use, design, material composition and technological characteristics, the GORE® DrySeal Sheath with hydrophilic coating is substantially equivalent to the 510(k) predicate device.

# **Testing in Support of Substantial Equivalence Determination**

Tests Performed to Establish Equivalence to Predicate Device(s)

Performance Testing	Applicable Test Standard
Lubricity	Comparative Analysis
Particulation	Comparative Analysis
Biocompatibility	ANSI/AAMI/ISO 10993-1
Sterilization Validation	ANSI/AAMI/ISO 11135-1
ì	AAMI TIR 28
Product Expiration Dating	Gore Internal Procedures

### Conclusion

The proposed device meets the performance criteria of design verification as specified by test protocols. The GORE® DrySeal Sheath with hydrophilic coating is substantially equivalent to the predicate device.





Food and Drug Administration 10903 New Hampshire Avenue Document Control Center – WO66-G609 Silver Spring, MD 20993-002

NOV 2 0 2012

W.L. GORE & Associates, Inc. c/o Alicia L. Hemphill Regulatory Affairs Associate 3450 West Kiltie Lane Flagstaff, AZ 86001

Re: K121234

Trade/Device Name: GORE® DrySeal Sheath with Hydrophilic Coating

Regulation Number: 21 CFR 870.1340 Regulation Name: Catheter Introducer

Regulatory Class: Class II

Product Code: DYB

Dated: November 13, 2012 Received: November 15, 2012

#### Dear Ms. Hemphill:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either Class II (Special Controls) or Class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act

or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <a href="http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm">http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm</a> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Matthew G. Digitally signed by Matthew G. Hillebraner DiviceUS, and S. Government, our Hills. Our FDR, our FDR,

Bram Zuckerman, M.D.
Director
Division of Cardiovascular Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

# INDICATION FOR USE

510(k) Number (if known):	K121234 TBD	
Device Name:	GORE® DrySeal Sheath with hydrophilic coating	
Intended Use / Indication For Use:	The GORE® DrySeal Sheath with hydrophilic coating is intended to be inserted in the vasculature to provide a conduit for the insertion of endovascular devices while minimizing blood loss associated with such insertions.	
•		
Prescription Use X (Part 21 CFR 801 Subpart D) (PLEASE DO NOT WRITE B)	AND/OR  Over-The-Counter Use  (21 CFR 801 Subpart C)  ELOW THIS LINE-CONTINUE ON ANOTHER PAGE  OF NEEDED)	

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)
Division of Cardiovascular Devices

510(k) Number K121234